<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01243411</url>
  </required_header>
  <id_info>
    <org_study_id>AUX-CC-802</org_study_id>
    <nct_id>NCT01243411</nct_id>
  </id_info>
  <brief_title>A Study of AA4500 in Men With Peyronie's Disease</brief_title>
  <official_title>A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 3, open-label study of the safety and efficacy of AA4500 0.58 mg in
      subjects with Peyronie's disease. Subjects will be screened for study eligibility within 21
      days before the initial injection of study drug in the first treatment cycle.

      After up to four treatment cycles, each subject will be followed for additional safety and
      efficacy assessments on Days 168 (± 7 days) and 252 (± 7 days) (nominal weeks 24 and 36).

      After the final injection of each treatment cycle, the investigator will model the plaque in
      an attempt to stretch or elongate the plaque. If the subject's penile curvature is reduced to
      &lt;15° after the first, second, or third cycle of injections or if the investigator determines
      further treatment is not clinically indicated (eg, adverse events; allergic reaction),
      subsequent treatment cycles will not be administered.

      Approximately 300 subjects will be enrolled.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change From Baseline in Penile Curvature</measure>
    <time_frame>Baseline and Week 36</time_frame>
    <description>A negative value in the percentage change from baseline in penile curvature deformity (angle measured in degrees) indicates less curvature.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)</measure>
    <time_frame>Baseline and Week 36</time_frame>
    <description>Peyronie's disease bother score range 0 (no issue or not at all bothered) to 4 (extremely bothered) on 4 questions; total score range 0 to 16. A decrease in the change from baseline total score in the Peyronie's disease bother domain of the PDQ is indicated by a negative number.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Severity of Peyronie's Disease Symptoms Domain of the PDQ</measure>
    <time_frame>Baseline and Week 36</time_frame>
    <description>Peyronie's disease symptoms (physical and psychological) severity score range 0 (none) to 4 (very severe) on 6 questions; total score range 0 to 24. A decrease in the change from baseline total score in the Peyronie's disease symptoms domain of the PDQ is indicated by a negative number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Penile Pain Domain of the PDQ in Subjects With Baseline Penile Pain Score ≥4</measure>
    <time_frame>Baseline and Week 36</time_frame>
    <description>Penile pain scale range 0 (no pain) to 10 (extreme pain) on 3 questions; total score range 0 to 30. A decrease in the change from baseline total score in the penile pain domain of the PDQ is indicated by a negative number. Subjects were required to have a penile pain score of 4 or greater at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A Responder Analysis Based on Subject Overall Global Assessment</measure>
    <time_frame>Week 36</time_frame>
    <description>Subject overall global assessment of Peyronie's disease score range -3 (much worse) to 3 (much improved). A score of 1 (improved in a small but important way), 2 (moderately improved), or 3 indicate a responder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Overall Satisfaction Domain of the International Index of Erectile Function (IIEF)</measure>
    <time_frame>Baseline and Week 36</time_frame>
    <description>Overall satisfaction domain of the IIEF score range 0 to 5 on 2 questions where higher scores indicate improved function or satisfaction; total score range 0 to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Penile Plaque Consistency</measure>
    <time_frame>Baseline and Week 36</time_frame>
    <description>Penile plaque consistency score range 1 (non-palpable) to 5 (hard). A decrease in the change from baseline in penile plaque consistency is indicated by a negative number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A Composite Responder Analysis Based on Change From Baseline in Penile Curvature and in the Peyronie's Disease Bother Score</measure>
    <time_frame>Week 36</time_frame>
    <description>A composite responder is indicated by
a percent reduction from baseline in penile curvature greater than or equal to the threshold, and
a reduction from baseline in Peyronie's disease bother score greater than or equal to the threshold, or change in the overall sexual activity within the last 3 months to having vaginal intercourse from no vaginal intercourse at screening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Penile Length</measure>
    <time_frame>Baseline and Week 36</time_frame>
    <description>A negative value represents a reduction in measurement from baseline.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">348</enrollment>
  <condition>Peyronie's Disease</condition>
  <arm_group>
    <arm_group_label>AA4500</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>collagenase clostridium histolyticum</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AA4500</intervention_name>
    <description>2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)</description>
    <arm_group_label>AA4500</arm_group_label>
    <other_name>XIAFLEX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        No subject should be enrolled until all eligibility criteria have been satisfied. Subjects
        who receive placebo in a previous Auxilium-sponsored study may enroll in this study
        provided they continue to meet the eligibility requirements. To qualify for the study a
        subject must:

          1. Be a male and be ≥ 18 years of age

          2. Be in a stable relationship with a female partner/spouse for at least 3 months before
             screening and be willing to have vaginal intercourse with that partner/spouse

          3. Have symptom(s) of Peyronie's disease for at least 12 months before the first dose of
             study drug and have evidence of stable disease as determined by the investigator

          4. Have penile curvature of at least 30° in the dorsal, lateral, or dorsal/lateral plane
             at screening. It must be possible to delineate the single plane of maximal curvature
             for evaluation during the study

          5. Be judged to be in good health, based upon the results of a medical history, physical
             examination, and laboratory profile

          6. Voluntarily sign and date an informed consent agreement approved by the Institutional
             Review Board/Independent Ethics Committee (IRB/IEC). The subject must also sign an
             authorization form to allow disclosure of his protected health information (PHI). The
             PHI authorization form and informed consent form may be an integrated form or may be
             separate forms depending on the institution

          7. Be able to read, complete and understand the various rating instruments in English or
             the appropriate local language for the country in which the study is being performed.

        Exclusion Criteria:

        A subject will be excluded from study participation if he:

          1. Has a penile curvature of less than 30° or greater than 90° at the screening visit

          2. Has any of the following conditions:

               -  Chordee in the presence or absence of hypospadias

               -  Thrombosis of the dorsal penile artery and/or vein

               -  Infiltration by a benign or malignant mass resulting in penile curvature

               -  Infiltration by an infectious agent, such as lymphogranuloma venereum

               -  Ventral curvature from any cause

               -  Presence of an active sexually transmitted disease

               -  Known active hepatitis B or C

               -  Known immune deficiency disease or be positive for human immunodeficiency virus
                  (HIV)

          3. Has previously undergone surgery for Peyronie's disease

          4. Fails to have an erection which in the opinion of the investigator is sufficient to
             accurately measure the subject's penile deformity after administration of
             prostaglandin E1 or trimix

          5. Has a calcified plaque as evident by appropriate radiographic evaluation, penile x-ray
             or penile ultrasound that would prevent proper injection of study medication (penile
             ultrasound only in EU countries). Non-contiguous stippling of calcium is acceptable
             for inclusion provided the calcium deposit does not interfere with the injection of
             AA4500 into the plaque

          6. Has an isolated hourglass deformity of the penis

          7. Has the plaque causing curvature of the penis located proximal to the base of the
             penis, so that the injection of the local anesthetic would interfere with the
             injection of AA4500 into the plaque

          8. Has previously received alternative medical therapies for Peyronie's disease
             administered by the intralesional route (including, but not limited to, steroids,
             verapamil, and the naturally occurring low molecular weight protein, interferon-α2b)
             within 3 months before the first dose of study drug or plans to use any of these
             medical therapies at any time during the study

          9. Has received alternative medical therapies for Peyronie's disease administered by the
             oral (including, but not limited to, vitamin E [&gt; 500 U], potassium aminobenzoate
             [Potaba], tamoxifen, colchicine, pentoxifylline, over-the-counter erectile dysfunction
             medications, or steroidal anti-inflammatory drugs) or topical routes (including, but
             not limited to, verapamil applied as a cream) within 3 months before the first dose of
             study drug or plans to use any of these medical therapies at any time during the study

         10. Has had extracorporeal shock wave therapy (ESWT) for the correction of Peyronie's
             disease within the 6-month period before screening or plans to have ESWT at any time
             during the study

         11. Has used any mechanical type device for correction of Peyronie's disease within the
             2-week period before screening or plans to use any these devices at any time during
             the study

         12. Has used a mechanical device to induce a passive erection within the 2-week period
             before screening or plans to use any of these devices at any time during the study

         13. Has significant erectile dysfunction that has failed to respond to oral treatment with
             phosphodiesterase type 5 (PDE5) inhibitors

         14. Has a penile Duplex Doppler ultrasound evaluation at screening that shows compromised
             penile hemodynamics that in the opinion of the investigator is clinically significant

         15. Has uncontrolled hypertension, as determined by the investigator

         16. Has a known recent history of stroke, bleeding, or other significant medical
             condition, which in the investigator's opinion would make the subject unsuitable for
             enrollment in the study

         17. Is unwilling or unable to cooperate with the requirements of the study including
             completion of all scheduled study visits

         18. Has received an investigational drug or treatment within 30 days before the first dose
             of study drug, except for subjects who receive one treatment cycle of AA4500 in Study
             AUX-CC-805

         19. Has a known systemic allergy to collagenase or any other excipient of AA4500

         20. Has a known allergy to any concomitant medication required as per the protocol

         21. Has received anticoagulant medication (except for ≤ 165 mg aspirin daily or ≤ 800 mg
             of over-the-counter NSAIDS daily) during the 7 days before each dose of study drug

         22. Has received any collagenase treatments within 30 days of the first dose of study
             drug, except for subjects who receive one treatment cycle of AA4500 in Study
             AUX-CC-805

         23. Has, at any time, received AA4500 for the treatment of Peyronie's disease, except for
             subjects who receive one treatment cycle of AA4500 in Study AUX-CC-805
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory J. Kaufman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Auxilium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urology Associates Medical Group</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Clinical Research Center, LLC</name>
      <address>
        <city>Middlebury</city>
        <state>Connecticut</state>
        <zip>06762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Urology Center, P.C.</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Specialists, S.C.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Indiana Research, LLC</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Urology, P.S.C.</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maimonides Medical Center, Division of Urology</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Urology Associates</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tristate Urologic Services PSC, Inc./ dba TUG Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologic Consultants of SE PA</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia-Sentara Medical Group</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Urology</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitiy Hospital, Aalborg Sygehus</name>
      <address>
        <city>Aalborg</city>
        <zip>DK-9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frederiksberg Hospital</name>
      <address>
        <city>Frederiksberg</city>
        <zip>DK-2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frederikssunds Hospital</name>
      <address>
        <city>Frederikssund</city>
        <zip>DK-3600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik for seksuelle dysfunktioner</name>
      <address>
        <city>Gentofte</city>
        <zip>DK-2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Edouar Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>F-69 437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Gabrielle</name>
      <address>
        <city>Saint Genis Laval</city>
        <zip>F-69230</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Freiburg, Abteilung Urologie</name>
      <address>
        <city>Freiburg</city>
        <zip>DE-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice of Urology/Andrology</name>
      <address>
        <city>Hamburg</city>
        <zip>DE-20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uro-Onkologische Praxis Dr. von Keitz</name>
      <address>
        <city>Marburg</city>
        <zip>DE-35039</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis Reutlingen</name>
      <address>
        <city>Reutlingen</city>
        <zip>DE-72764</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Tubingen</name>
      <address>
        <city>Tubingen</city>
        <zip>DE-72096</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Naples &quot;Federico II&quot;</name>
      <address>
        <city>Naples</city>
        <zip>I-80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitiy Tor Vergatat of Rome</name>
      <address>
        <city>Rome</city>
        <zip>I-00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waitemata Urology Research North Shore Hospital</name>
      <address>
        <city>Takapuna</city>
        <state>Auckland</state>
        <zip>0622</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tauranga Urology Research Ltd.</name>
      <address>
        <city>Tauranga</city>
        <state>Bay of Plenty</state>
        <zip>3140</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primorus Clinical Trials Ltd.</name>
      <address>
        <city>Christchurch</city>
        <state>Canterbury</state>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CURT Medical Trials Trust Board Inc.</name>
      <address>
        <city>Christchurch</city>
        <state>Canterbury</state>
        <zip>8014</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Points Research Ltd.</name>
      <address>
        <city>Whangarei</city>
        <state>Northland</state>
        <zip>0112</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellington Urology Associates</name>
      <address>
        <city>Wellington South</city>
        <state>Wellington</state>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>ES-08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Zarzuela</name>
      <address>
        <city>Madrid</city>
        <zip>ES-28043</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialistmottagningen i urologi</name>
      <address>
        <city>Goteborg</city>
        <zip>SE-405 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carlshamns Specialistklinik</name>
      <address>
        <city>Karlshamn</city>
        <zip>SE-374 35</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuse</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Peter's Andrology Centre</name>
      <address>
        <city>London</city>
        <zip>W1G 6BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunderland Royal Hospital</name>
      <address>
        <city>Sunderland</city>
        <zip>SR4 &amp;TP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2010</study_first_submitted>
  <study_first_submitted_qc>November 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2010</study_first_posted>
  <results_first_submitted>February 4, 2015</results_first_submitted>
  <results_first_submitted_qc>March 31, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 15, 2015</results_first_posted>
  <last_update_submitted>September 7, 2017</last_update_submitted>
  <last_update_submitted_qc>September 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peyronie's Disease, penile plaque, penile curvature</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Penile Induration</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Includes all subjects who were enrolled and received at least 1 dose of study drug; subjects who were enrolled but not treated were excluded from the population</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AA4500</title>
          <description>collagenase clostridium histolyticum
AA4500: 2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="347"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="306"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AA4500</title>
          <description>collagenase clostridium histolyticum
AA4500: 2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="347"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="289"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.5" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="325"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="333"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change From Baseline in Penile Curvature</title>
        <description>A negative value in the percentage change from baseline in penile curvature deformity (angle measured in degrees) indicates less curvature.</description>
        <time_frame>Baseline and Week 36</time_frame>
        <population>Efficacy is based on the modified intent-to-treat (mITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500</title>
            <description>collagenase clostridium histolyticum
AA4500: 2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Penile Curvature</title>
          <description>A negative value in the percentage change from baseline in penile curvature deformity (angle measured in degrees) indicates less curvature.</description>
          <population>Efficacy is based on the modified intent-to-treat (mITT) population.</population>
          <units>percentage of curvature change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.4" spread="25.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)</title>
        <description>Peyronie's disease bother score range 0 (no issue or not at all bothered) to 4 (extremely bothered) on 4 questions; total score range 0 to 16. A decrease in the change from baseline total score in the Peyronie's disease bother domain of the PDQ is indicated by a negative number.</description>
        <time_frame>Baseline and Week 36</time_frame>
        <population>Efficacy is based on the mITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500</title>
            <description>collagenase clostridium histolyticum
AA4500: 2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)</title>
          <description>Peyronie's disease bother score range 0 (no issue or not at all bothered) to 4 (extremely bothered) on 4 questions; total score range 0 to 16. A decrease in the change from baseline total score in the Peyronie's disease bother domain of the PDQ is indicated by a negative number.</description>
          <population>Efficacy is based on the mITT population.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="3.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Severity of Peyronie's Disease Symptoms Domain of the PDQ</title>
        <description>Peyronie's disease symptoms (physical and psychological) severity score range 0 (none) to 4 (very severe) on 6 questions; total score range 0 to 24. A decrease in the change from baseline total score in the Peyronie's disease symptoms domain of the PDQ is indicated by a negative number.</description>
        <time_frame>Baseline and Week 36</time_frame>
        <population>Efficacy is based on the mITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500</title>
            <description>collagenase clostridium histolyticum
AA4500: 2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Severity of Peyronie's Disease Symptoms Domain of the PDQ</title>
          <description>Peyronie's disease symptoms (physical and psychological) severity score range 0 (none) to 4 (very severe) on 6 questions; total score range 0 to 24. A decrease in the change from baseline total score in the Peyronie's disease symptoms domain of the PDQ is indicated by a negative number.</description>
          <population>Efficacy is based on the mITT population.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="5.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Penile Pain Domain of the PDQ in Subjects With Baseline Penile Pain Score ≥4</title>
        <description>Penile pain scale range 0 (no pain) to 10 (extreme pain) on 3 questions; total score range 0 to 30. A decrease in the change from baseline total score in the penile pain domain of the PDQ is indicated by a negative number. Subjects were required to have a penile pain score of 4 or greater at baseline.</description>
        <time_frame>Baseline and Week 36</time_frame>
        <population>Efficacy is based on the mITT population; this population only includes those subjects in the mITT population with a baseline penile pain score of 4 or greater.</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500</title>
            <description>collagenase clostridium histolyticum
AA4500: 2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Penile Pain Domain of the PDQ in Subjects With Baseline Penile Pain Score ≥4</title>
          <description>Penile pain scale range 0 (no pain) to 10 (extreme pain) on 3 questions; total score range 0 to 30. A decrease in the change from baseline total score in the penile pain domain of the PDQ is indicated by a negative number. Subjects were required to have a penile pain score of 4 or greater at baseline.</description>
          <population>Efficacy is based on the mITT population; this population only includes those subjects in the mITT population with a baseline penile pain score of 4 or greater.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>A Responder Analysis Based on Subject Overall Global Assessment</title>
        <description>Subject overall global assessment of Peyronie's disease score range -3 (much worse) to 3 (much improved). A score of 1 (improved in a small but important way), 2 (moderately improved), or 3 indicate a responder.</description>
        <time_frame>Week 36</time_frame>
        <population>Efficacy is based on the mITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500</title>
            <description>collagenase clostridium histolyticum
AA4500: 2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)</description>
          </group>
        </group_list>
        <measure>
          <title>A Responder Analysis Based on Subject Overall Global Assessment</title>
          <description>Subject overall global assessment of Peyronie's disease score range -3 (much worse) to 3 (much improved). A score of 1 (improved in a small but important way), 2 (moderately improved), or 3 indicate a responder.</description>
          <population>Efficacy is based on the mITT population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responder Status - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responder Status - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Overall Satisfaction Domain of the International Index of Erectile Function (IIEF)</title>
        <description>Overall satisfaction domain of the IIEF score range 0 to 5 on 2 questions where higher scores indicate improved function or satisfaction; total score range 0 to 10.</description>
        <time_frame>Baseline and Week 36</time_frame>
        <population>Efficacy is based on the mITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500</title>
            <description>collagenase clostridium histolyticum
AA4500: 2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Overall Satisfaction Domain of the International Index of Erectile Function (IIEF)</title>
          <description>Overall satisfaction domain of the IIEF score range 0 to 5 on 2 questions where higher scores indicate improved function or satisfaction; total score range 0 to 10.</description>
          <population>Efficacy is based on the mITT population.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Penile Plaque Consistency</title>
        <description>Penile plaque consistency score range 1 (non-palpable) to 5 (hard). A decrease in the change from baseline in penile plaque consistency is indicated by a negative number.</description>
        <time_frame>Baseline and Week 36</time_frame>
        <population>Efficacy is based on the mITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500</title>
            <description>collagenase clostridium histolyticum
AA4500: 2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Penile Plaque Consistency</title>
          <description>Penile plaque consistency score range 1 (non-palpable) to 5 (hard). A decrease in the change from baseline in penile plaque consistency is indicated by a negative number.</description>
          <population>Efficacy is based on the mITT population.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>A Composite Responder Analysis Based on Change From Baseline in Penile Curvature and in the Peyronie's Disease Bother Score</title>
        <description>A composite responder is indicated by
a percent reduction from baseline in penile curvature greater than or equal to the threshold, and
a reduction from baseline in Peyronie's disease bother score greater than or equal to the threshold, or change in the overall sexual activity within the last 3 months to having vaginal intercourse from no vaginal intercourse at screening.</description>
        <time_frame>Week 36</time_frame>
        <population>Composite responder analysis is based on the intent-to-treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500</title>
            <description>collagenase clostridium histolyticum
AA4500: 2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)</description>
          </group>
        </group_list>
        <measure>
          <title>A Composite Responder Analysis Based on Change From Baseline in Penile Curvature and in the Peyronie's Disease Bother Score</title>
          <description>A composite responder is indicated by
a percent reduction from baseline in penile curvature greater than or equal to the threshold, and
a reduction from baseline in Peyronie's disease bother score greater than or equal to the threshold, or change in the overall sexual activity within the last 3 months to having vaginal intercourse from no vaginal intercourse at screening.</description>
          <population>Composite responder analysis is based on the intent-to-treat (ITT) population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responder - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responder - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responder - Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Penile Length</title>
        <description>A negative value represents a reduction in measurement from baseline.</description>
        <time_frame>Baseline and Week 36</time_frame>
        <population>Efficacy is based on the mITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500</title>
            <description>collagenase clostridium histolyticum
AA4500: 2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Penile Length</title>
          <description>A negative value represents a reduction in measurement from baseline.</description>
          <population>Efficacy is based on the mITT population.</population>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AA4500</title>
          <description>collagenase clostridium histolyticum
AA4500: 2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device occlusion</sub_title>
                <description>Right coronary artery in-stent occlusion</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Fracture of penis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Penile haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="297" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="171" subjects_affected="93" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" events="139" subjects_affected="84" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="68" subjects_affected="40" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Penile haematoma</sub_title>
                <counts group_id="E1" events="356" subjects_affected="178" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Penile pain</sub_title>
                <counts group_id="E1" events="261" subjects_affected="120" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Penile swelling</sub_title>
                <counts group_id="E1" events="138" subjects_affected="91" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Penile haemorrhage</sub_title>
                <description>penile ecchymosis</description>
                <counts group_id="E1" events="203" subjects_affected="79" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Penile oedema</sub_title>
                <counts group_id="E1" events="120" subjects_affected="49" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Painful erection</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Coordinator</name_or_title>
      <organization>Endo Pharmaceuticals, Inc.</organization>
      <email>clinicalsite.inquiries@endo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

